Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNYR 
Synergy CHC Corp. Common Stock (SNYR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: SNYR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.77% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 24.17M USD | Price to earnings Ratio 5.68 | 1Y Target Price 10 |
Price to earnings Ratio 5.68 | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 0.85 | 52 Weeks Range 1.30 - 10.00 | Updated Date 09/15/2025 |
52 Weeks Range 1.30 - 10.00 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.61% | Operating Margin (TTM) 19.96% |
Management Effectiveness
Return on Assets (TTM) 24.16% | Return on Equity (TTM) -361.12% |
Valuation
Trailing PE 5.68 | Forward PE 4.8 | Enterprise Value 49589697 | Price to Sales(TTM) 0.72 |
Enterprise Value 49589697 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 1.47 | Enterprise Value to EBITDA 5.64 | Shares Outstanding 11191900 | Shares Floating 4053104 |
Shares Outstanding 11191900 | Shares Floating 4053104 | ||
Percent Insiders 56.75 | Percent Institutions 3.82 |
Upturn AI SWOT
Synergy CHC Corp. Common Stock
Company Overview
History and Background
Synergy CHC Corp. was a consumer health company that focused on acquiring and developing branded consumer healthcare products. Information on its specific founding year, milestones, and evolution is limited as it ceased being a publicly traded company after being acquired.
Core Business Areas
- Branded Consumer Healthcare Products: Focused on developing and marketing a portfolio of branded consumer healthcare products, often acquired from larger pharmaceutical companies.
Leadership and Structure
Due to Synergy CHC Corp.'s acquisition and subsequent cessation of being a publicly traded company, current leadership and organizational structure are not publicly available.
Top Products and Market Share
Key Offerings
- Cold-EEZE: A popular over-the-counter cold remedy. Market share information is difficult to pinpoint precisely post-acquisition. Competitors include Zicam, Airborne, and generic zinc lozenges.
Market Dynamics
Industry Overview
The consumer healthcare industry is characterized by over-the-counter medications, vitamins, supplements, and personal care products. Growth is driven by aging populations, increasing health awareness, and a shift towards self-medication.
Positioning
Synergy CHC Corp. aimed to occupy a niche in the consumer healthcare market by acquiring and revitalizing established brands. Their competitive advantage hinged on effective marketing and distribution.
Total Addressable Market (TAM)
The global consumer healthcare market is estimated to be in the hundreds of billions of dollars. Synergy CHC Corp.'s positioning focused on capturing segments within this large TAM through specific product categories.
Upturn SWOT Analysis
Strengths
- Established Brand Portfolio
- Effective Marketing Strategies
- Distribution Network
- Acquisition Expertise
Weaknesses
- Reliance on Acquired Brands
- Limited Innovation Pipeline
- Potential Debt Burden from Acquisitions
- Vulnerability to Generic Competition
Opportunities
- Expansion into New Geographic Markets
- Product Line Extensions
- Strategic Partnerships
- Further Acquisitions of Complementary Brands
Threats
- Increased Competition from Larger Players
- Changing Consumer Preferences
- Regulatory Changes in the Healthcare Industry
- Economic Downturn Affecting Consumer Spending
Competitors and Market Share
Key Competitors
- PG
- JNJ
- BAYRY
Competitive Landscape
Before its acquisition, Synergy CHC Corp. competed with major consumer healthcare companies by focusing on niche markets and acquired brands. Its success depended on effective marketing, distribution, and brand revitalization.
Growth Trajectory and Initiatives
Historical Growth: Historical growth analysis is limited by the company's delisting.
Future Projections: Future projections are unavailable as the company is no longer publicly traded.
Recent Initiatives: Recent initiatives are not publicly disclosed due to the change in company status.
Summary
Synergy CHC Corp. was a consumer health company focused on acquiring and growing established brands. Its strategy relied on successful brand revitalization and effective marketing. The company faced challenges from larger competitors and the need for continuous innovation. Its future success depended on navigating the evolving consumer healthcare landscape before its acquisition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Publicly available historical information, market reports, industry analysis.
Disclaimers:
The information provided is based on limited publicly available data. The analysis and rating are subjective and should not be considered investment advice. Data after the company's acquisition is unavailable.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synergy CHC Corp. Common Stock
Exchange NASDAQ | Headquaters Westbrook, ME, United States | ||
IPO Launch date 2016-01-04 | CEO & Chairman Mr. Jack Ross | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 21 | Website https://synergychc.com |
Full time employees 21 | Website https://synergychc.com | ||
Synergy CHC Corp. provides consumer health care, beauty, and lifestyle products in the United States, Canada, and the United Kingdom. It offers brain health nutritional supplements under the FOCUSfactor brand name; and lifestyle and wellness products and accessories, including tea, shakes, lollipops, supplements, apparel, and exercise accessories under the Flat Tummy brand name. The company also provides hand care products under the Hand MD brand name; beauty products for the eyes, lips, brows, cheeks, and skin under the Perfekt Beauty brand; shapewear, bralettes, and panties under Sneaky Vaunt brand; eyelash enhancement products under The Queen Pegasus brand; topical treatments for neuropathic pain under Neuragen brand; and over-the-counter medications under UrgentRx brand. It sells its products through club, mass drug, and other retailers. The company was formerly known as Synergy Strips Corp. and changed its name to Synergy CHC Corp. in August 2015. The company was incorporated in 2010 and is based in Westbrook, Maine.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.